Neuregulin-1β Improves Uremic Cardiomyopathy and Renal Dysfunction in Rats
Márta Sárközy, Simon Watzinger, Zsuzsanna Z. A. Kovács, Eylem Acar, Fanni Márványkövi, Gergő Szűcs, Gülsüm Yilmaz Lauber, Zsolt Galla, Andrea Siska, Imre Földesi, Attila Fintha, András Kriston, Ferenc Kovács, Péter Horváth, Bence Kővári, Gábor Cserni, Tibor Krenács, Petra Lujza Szabó, Gábor Szabó, Péter Monostori, Karin Zins, Dietmar Abraham, Tamás Csont, Péter Pokreisz, Bruno K. Podesser, Attila Kiss
Abstract
Chronic kidney disease is a global health problem affecting 10% to 12% of the population. Uremic cardiomyopathy is often characterized by left ventricular hypertrophy, fibrosis, and diastolic dysfunction. Dysregulation of neuregulin-1β signaling in the heart is a known contributor to heart failure. The systemically administered recombinant human neuregulin-1β for 10 days in our 5/6 nephrectomy-induced model of chronic kidney disease alleviated the progression of uremic cardiomyopathy and kidney dysfunction in type 4 cardiorenal syndrome. The currently presented positive preclinical data warrant clinical studies to confirm the beneficial effects of recombinant human neuregulin-1β in patients with chronic kidney disease.